Literature DB >> 12233879

Reduction of serum soluble CD26/dipeptidyl peptidase IV enzyme activity and its correlation with disease activity in systemic lupus erythematosus.

Hiroshi Kobayashi1, Osamu Hosono, Tsuneyo Mimori, Hiroshi Kawasaki, Nam Hoang Dang, Hirotoshi Tanaka, Chikao Morimoto.   

Abstract

OBJECTIVE: CD26 is the cell surface activation antigen with dipeptidyl peptidase IV (DPPIV) enzyme activity at the extracellular domain that is preferentially expressed on memory T cells and has a role in T cell immune responses. The soluble form of CD26 is present in serum and recombinant soluble CD26 (rsCD26) can enhance in vitro antigen-specific T cell responses. To determine the role of soluble CD26 (sCD26) in the pathophysiology of patients with systemic lupus erythematosus (SLE), we measured levels of sCD26 and its specific DPPIV activity in serum.
METHODS: Serum sCD26 levels and DPPIV activity were measured by sandwich ELISA in 53 patients with SLE and 54 healthy controls. Serum sCD26 was identified by immunoprecipitation and immunoblot analysis. Expression of CD26 on T cells was analyzed by flow cytometry.
RESULTS: Serum levels of sCD26 and its specific DPPIV activity were significantly decreased in SLE and were inversely correlated with SLE disease activity index score, but not with clinical variables or clinical subsets of SLE. Close correlation between sCD26/DPPIV and disease activity was observed in the longitudinal study.
CONCLUSION: Serum levels of sCD26 may be involved in the pathophysiology of SLE, and appear to be useful as a new disease activity measure for SLE.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12233879

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  22 in total

1.  Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: A nationwide population-based cohort study.

Authors:  Jong-Mi Seong; Jeong Yee; Hye Sun Gwak
Journal:  Br J Clin Pharmacol       Date:  2019-06-04       Impact factor: 4.335

2.  Comparison of two commercial ELISAs against an in-house ELISA for measuring soluble CD26 in human serum.

Authors:  Kei Ohnuma; Tatsuhiko Saito; Ryou Hatano; Osamu Hosono; Satoshi Iwata; Nam H Dang; Hiroki Ninomiya; Chikao Morimoto
Journal:  J Clin Lab Anal       Date:  2014-03-28       Impact factor: 2.352

3.  Soluble CD26/CD30 levels in visceral leishmaniasis: markers of disease activity.

Authors:  S Ajdary; F Riazi-Rad; R Jafari-Shakib; M Mohebbali
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

4.  Serum levels of soluble CD26 and CD30 and their clinical significance in patients with rheumatoid arthritis.

Authors:  Hasan Ulusoy; Ayhan Kamanli; Necip Ilhan; Omer Kuru; Sule Arslan; Gokhan Alkan; Salih Ozgocmen
Journal:  Rheumatol Int       Date:  2011-12-23       Impact factor: 2.631

5.  Circulating CD26 is negatively associated with inflammation in human and experimental arthritis.

Authors:  Nathalie Busso; Nicolai Wagtmann; Christian Herling; Veronique Chobaz-Péclat; Angelika Bischof-Delaloye; Alexander So; Eric Grouzmann
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

6.  Higher serum DPP-4 enzyme activity and decreased lymphocyte CD26 expression in type 1 diabetes.

Authors:  Tímea Varga; Anikó Somogyi; Gábor Barna; Barna Wichmann; Géza Nagy; Károly Rácz; László Selmeci; Gábor Firneisz
Journal:  Pathol Oncol Res       Date:  2011-07-22       Impact factor: 3.201

7.  Potential of soluble CD26 as a serum marker for colorectal cancer detection.

Authors:  Oscar J Cordero; Monica Imbernon; Loretta De Chiara; Vicenta S Martinez-Zorzano; Daniel Ayude; Maria Paez de la Cadena; F Javier Rodriguez-Berrocal
Journal:  World J Clin Oncol       Date:  2011-06-10

8.  Rhinorrhea, cough and fatigue in patients taking sitagliptin.

Authors:  James N Baraniuk; Mary J Jamieson
Journal:  Allergy Asthma Clin Immunol       Date:  2010-05-12       Impact factor: 3.406

9.  Fecal Dipeptidyl Peptidase-4: An Emergent Biomarker in Inflammatory Bowel Disease.

Authors:  Pedro Pinto-Lopes; Francisco Melo; Joana Afonso; Rui Pinto-Lopes; Cátia Rocha; Daniel Melo; Guilherme Macedo; Cláudia Camila Dias; Fátima Carneiro; Fernando Magro
Journal:  Clin Transl Gastroenterol       Date:  2021-03-10       Impact factor: 4.396

10.  Soluble CD26 is inversely Associated with Disease Severity in Patients with Chronic Eosinophilic Pneumonia.

Authors:  Osamu Matsuno; Eishi Miyazaki; Shinichi Nureki; Takuya Ueno; Masaru Ando; Toshihide Kumamoto
Journal:  Biomark Insights       Date:  2007-02-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.